- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03856762
Dietary Pattern and Metabolic Health Study
This is a single-blind, randomized trial. Based on inclusion and exclusion criteria, 253 eligible volunteers, who were 25-60 years old, with overweight/obese and prediabetes are assigned to one of three dietary patterns: healthy Jiangnan, restricted-calorie; Mediterranean, restricted-calorie; or typical Shanghai, restricted-calorie.
The Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences(CAS) cooperated with Ruijin Hospital to conduct the study which is funded by the CAS. The study' protocol has been approved by the Ethics Committee of Shanghai Institutes for Biological Sciences. The main purpose of this study is to clarify: the efficacy of traditional Jiangnan dietary pattern, Mediterranean dietary pattern and the current Shanghai dietary pattern in improving overweight/obesity, glucose homeostasis, other cardiovascular metabolic risk factors and their main regulatory factors in Chinese.
Study Overview
Status
Conditions
Detailed Description
Nowadays, the prevalence of type 2 diabetes and its related metabolic diseases is rapidly rising in China. Obesity and early pathoglycemia will increase the risk of diabetes and related cardiovascular diseases severely. Therefore, more effective methods and strategies need to be found to reduce body weight, improve pathoglycemia, and control the development of this high-risk group to type 2 diabetes. As the most popular healthy dietary pattern in the world, the role of Mediterranean diet in the prevention of type 2 diabetes remains unclear. In addition, the protective role of Chinese traditional dietary pattern with lots of plant-based foods in the region of Jiangnan has not been clarified through intervention studies. Therefore, it is urgent to explore the feasibility and effectiveness of traditional Jiangnan diet and Mediterranean diet through dietary intervention studies in Chinese.
The effectiveness of healthy dietary patterns can be further enhanced by limiting dietary intake to achieve weight loss. Recently, the Spainish study found that energy-restricted Mediterranean diet + physical activity + behavioral interventions are more conducive to weight loss in overweight/obesity with prediabetes/type 2 diabetes compared with conventional Mediterranean dietary interventions. The 2019 Diabetes Management Standard of American Diabetes Association re-emphasizes the importance of moderate weight loss for delaying the progression of type 2 diabetes, and recommends that a reduction in dietary intake is 500-750 kcal/day to reach 1-2 pounds per week is suitable. At the same time, the American Clinical Endocrine Society and the American Endocrine Society have also updated the 2019 Comprehensive Management Guide for Type 2 Diabetes. The new guidelines point out that all overweight or obese patients with prediabetes or type 2 diabetes should pay attention to weight loss. And weight loss treatment should include specific lifestyle interventions, including calorie-restricted healthy dietary plan, physical activity and behavioral interventions.
Dietary intervention studies in the past mainly relied on dietary education. However, this study now provides a healthy and reasonable dietary model for the Chinese population through lifestyle intervention to clarify the improvement of cardiovascular metabolic risk such as overweight/obesity, glucose homeostasis, and the scientific basis for establishing a healthy dietary model which is suitable for Chinese population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200031
- Ruijin hospital; SAIC FAW-Volkswagen Automobile Co
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 25 to 60 years old
- 24.0 ≤ BMI ≤ 40.0 kg/m2
- fasting glucose≥5.6 mmol/L
Exclusion Criteria:
- Diabetes or use of insulin or other hypoglycemic medications
- Pregnancy or lactation
- Trying to change body weight in the way
- Use of antibiotic in the preceding 3 months for 3-serial days
- Obvious changes of medication in the preceding 3 months
- History of drug or alcohol abuse or other substance abuse; (Alcohol abuse is defined as regular alcohol consumption > 40 g/day)
- Any severe liver or renal diseases
- Severe gastrointestinal diseases
- Surgical events preceding 1 year (except appendicitis or hernia surgery)
- Severe cardiovascular or cerebrovascular diseases or phase three hypertension
- Implantation of heart stent
- Cancer or receiving radiotherapy and chemotherapy within 5 years
- Hyperthyroidism or hypothyroidism
- Suffering from hepatitis B, tuberculosis, AIDS and other infectious diseases
- Any mental disorders or current use of antidepressants
- Food contraindications or allergies to foods included in the intervention
- Cognitive disability
- Participated in any other clinical studies within 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Traditional Jiangnan diet
Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
|
traditional Jiangnan diet supplement from Monday to Friday for six months
|
|
EXPERIMENTAL: Mediterranean diet
Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
|
Mediterranean diet supplement from Monday to Friday for six months
|
|
EXPERIMENTAL: Current Shanghai diet
Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
|
current Shanghai diet supplement from Monday to Friday for six months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight
Time Frame: 6 months
|
Body weight will be assessed by electronic scale (Seca-882; ScalesGalore) during each visit and Wi-Fi scale at home
|
6 months
|
|
Glucose homeostasis
Time Frame: 6 months
|
Glucose homeostasis will be assessed by Continuous Glucose Monitoring(FreeStyle Libre)
|
6 months
|
|
Glucose
Time Frame: 6 months
|
Glucose will be assessed by oral glucose tolerance test
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Abdominal fat
Time Frame: 6 months
|
Abdominal fat will be assessed using Magnetic Resonance Imaging
|
6 months
|
|
Blood pressure
Time Frame: 6 months
|
Both systolic pressure and diastolic pressure will be assessed using electronic blood pressure monitor (Omron HEM-7000)
|
6 months
|
|
Total cholesterol
Time Frame: 6 months
|
Total cholesterol will be assessed using an automatic biochemical analyzer
|
6 months
|
|
Triglyceride
Time Frame: 6 months
|
Triglyceride will be assessed using an automatic biochemical analyzer
|
6 months
|
|
LDL-C
Time Frame: 6 months
|
LDL-C will be assessed using an automatic biochemical analyzer
|
6 months
|
|
HDL-C
Time Frame: 6 months
|
HDL-C will be assessed using an automatic biochemical analyzer
|
6 months
|
|
HbA1c
Time Frame: 6 months
|
HbA1c will be assessed using liquid Chromatograph Mass Spectrometer
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAS-HDP-201902
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Weight Loss
-
United States Army Research Institute of Environmental...USDA Grand Forks Human Nutrition Research Center; Eastern Michigan UniversityCompletedWeight Loss | Bone Loss | Muscle LossUnited States
-
Case Comprehensive Cancer CenterUniversity Hospitals Seidman Cancer CenterRecruitingUnintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking CombinUnintended Weight LossUnited States
-
HealthPartners InstituteNational Cancer Institute (NCI)Completed
-
Zhen Jun WangUnknownSleeve Gastrectomy | Excessive Weight Loss | Total Weight Loss | Jejunojejunal Bypass | UncutChina
-
Dana-Farber Cancer InstituteCompletedWeight Loss Program After Cancer DiagnosisUnited States
-
Medical University of ViennaCompleted
-
Power Life Sciences Inc.Not yet recruitingGastric Bypass | Weight Loss Surgery
-
University at BuffaloHarvard Medical School (HMS and HSDM)TerminatedWeight Loss | Appetite LossUnited States
-
Duke UniversityNational Institute on Aging (NIA)Completed
-
Drexel UniversityUniversity of PennsylvaniaCompletedObesity | Overweight | Weight Loss MaintenanceUnited States
Clinical Trials on traditional Jiangnan diet
-
Duke UniversityNorth Dakota Beef CommissionCompleted
-
Miguel López MorenoIMDEA Food; Hospital Clinico Universitario San Cecilio; Hospital Universitario...Not yet recruitingMetabolic Dysfunction-associated Liver DiseaseSpain
-
Kyorin UniversityJapanese Society for the Promotion of ScienceCompletedBlood PressureJapan
-
USDA Grand Forks Human Nutrition Research CenterCompletedPhysical Activity | Sedentary BehaviorUnited States
-
Wake Forest University Health SciencesCompleted
-
Penn State UniversityAlliance for Potato Research & EducationNot yet recruitingPrediabetes
-
Firat UniversityThe Scientific and Technological Research Council of TurkeyCompletedMediterranean Diet | Multiple Sclerosis (MS) - Relapsing-remittingTurkey (Türkiye)
-
Seattle Children's HospitalCompleted
-
Universitaire Ziekenhuizen KU LeuvenRecruitingDiabetes Mellitus, Type 1Belgium
-
Société des Produits Nestlé (SPN)CompletedToddlers Bone MetabolismPhilippines